Premature Neonate
Conditions
Keywords
Less Invasive Surfactant Administration (LISA), Sedation, RDS treated by CPAP requiring surfactant, Sedation during intra tracheal surfactant administration by the LISA method, Available intravenous line
Brief summary
Respiratory distress syndrome (RDS) caused by surfactant deficiency remains one of the major reasons of morbi-mortality in preterm infants and affects 85% of preterm babies born less than 32 week gestational age (wGA). The strategy to manage RDS relies on the use of surfactant and non-invasive nasal ventilation, to limit tracheal mechanical ventilation. During recent years, surfactant administration through a thin catheter in spontaneously breathing preterm used in association with continuous positive airway pressure (CPAP) has emerged as a new approach for treating neonates with respiratory failure. The main objectives of Less Invasive Surfactant Administration (LISA) are to avoid endotracheal mechanical ventilation and its side effects including bronchopulmonary dysplasia. The LISA premedication procedure still under debate, because only 1 trial use analgesia or sedation during procedure. This reflects neonatologists concerns about side effects (apnea and the need for mechanical ventilation) of this premedication. This study aims to optimize sedation during LISA procedure by evaluating pain score with Ketamine or Protofol sedation, in Neonatal intensive care unit (NICU) patients with RDS.
Detailed description
Systematic reviews of the prospective studies performed suggest that among preterm infants, the use of LISA was associated with the lowest likelihood of the composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age when compared with the other ventilation strategies for preterm infants. Further studies are needed to optimize the indications and identify adequate strategies for premedication that preserve respiratory function and which limits pain and cardio-respiratory instability associated with laryngeal exposure without increasing risks of complications. According to a recent European survey, only 48% of neonatologists perform LISA with sedation. In a recent retrospective study, Dekker showed a more favorable COMFORTneo score with Propofol versus without, similar rates of intubation during LISA. Ketamine infusion has been used in several NICUs with few reported effects on respiratory function, but without publication. No prospective studies exist on LISA premedication. This study aims to optimize sedation during LISA in NICU patients with RDS. Comparing Ketamine and propofol sedation with rate of mechanical tracheal ventilation from the start of the LISA procedure up to 2 hours of life, in the NICU of Arnaud de Villeneuve University Hospital of Montpellier (France).
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Infant born below 30 wGA with RDS treated by CPAP requiring surfactant * Available IV line * Admission to the NICU of Montpellier University Hospital Centre in the first 24 hours of life
Exclusion criteria
* maternal general anesthesia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of mechanical ventilation (MV) from the start of the LISA procedure up to 2 hours of life | 2 hours after LISA procedure | The Investigators would like to evaluating the need for MV within the time of the LISA procedure and up to 2 hours of life among preterm babies less than 30wGA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiorespiratory parameters | 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age | Cardiorespiratory parameters before and at 5, 30 minutes after the drug injection: blood pressure |
| Rate of MV from the start of the LISA procedure up to 24 and 72 hours of life and causes of failure | 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age | Rate of MV from the start of the LISA procedure up to 24 and 72 hours of life and causes of failure (apnea, need surfactant) |
| To assess Neonatal morbidity at 36 wGA | 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age | Neonatal morbidity at 36 wGA |
| To assess mortality at 36 wGA | 5 and 30 minutes after the drug injection 24 and 72 hours of life and 36 week gestational age | Mortality at 36 wGA |
Countries
France